B>R>E>A>K>I>N>G NEWS!
China lying about coming out of zero Covid restrictions?
China lying about coming out of zero Covid restrictions?
GBA Presents: RADIO SAVANT-!
- Thread starter stonedinvestor
- Start date
Stoney, and you lost 10% on the bid/ask spread.<<2 Possible Gummies>>
Kodiak Sciences initiated with an Overweight at Capital One 08:27 KOD Capital One analyst Zegbeh Jallah initiated coverage of Kodiak Sciences with an Overweight rating and $24 price target. Kodiak's long-acting anti-VEGF drug Tarcocimab, or KSI-301, is currently in Phase 3 studies for DME, wAMD and NPDR with data expected in 2023, Jallah tells investors. Data from the Phase 3 BEACON study presented in September reaffirmed KSI-301's longer-acting potential and clean safety profile and "sets positive expectations for the 2023 readouts," but Jallah believes that macro events affecting the market and a "flight of investors out of the biotech sector" led to a muted reaction to the data, the analyst added.
KOD
$7.25-0.31(-4.10%)11:00 AM 11/14/22
NASDAQ |$USD |Pre-Market:$7.51+0.26(+3.59%)3:48 AM
Small reaction-
/////////////////////
NeuroSense rises 16% on U.S. FDA clearance to begin trial of ALS treatment
Watch For Gummy!// wait for GO TIME
NRSN
$1.580.06(+4.30%)10:59 AM 11/14/22
NASDAQ |$USD |Pre-Market:$1.74+0.17(+10.48%)<----------
BUY VAN!!!!!
& Sell! Just made you 5%
NRSN NeuroSense Therapeutics Ltd.
$1.580.06(+4.30%)10:59 AM 11/14/22
NASDAQ |$USD |Pre-Market:$1.81+0.24(+14.92%)4:15 AM
These penny stocks are stupid.
Try to keep things above $7 for thread integrity. I shouldn't have even posted Gingko.
Bad news.My wife goes to this building for her work a few times a week...
Van How can I lose money without buy yet? Only you can dream up these scenarios...
Wait for GO TIME
The real breaking news will turn out to be... Biden talked XI into using Moderna or Pfizer
~the savant
Just going by what you said.
I can't keep up.
[
BUY VAN!!!!!
& Sell! Just made you 5%
/QUOTE]
Is this some sort of competition to CHWY?
We have offered. But they will steal the technology so MRNA is only half way in on the concept. Initially they were gung ho for China>
Just going by what you said.
<<2 Possible Gummies>>
Kodiak Sciences initiated with an Overweight at Capital One 08:27 KOD Capital One analyst Zegbeh Jallah initiated coverage of Kodiak Sciences with an Overweight rating and $24 price target. Kodiak's long-acting anti-VEGF drug Tarcocimab, or KSI-301, is currently in Phase 3 studies for DME, wAMD and NPDR with data expected in 2023, Jallah tells investors. Data from the Phase 3 BEACON study presented in September reaffirmed KSI-301's longer-acting potential and clean safety profile and "sets positive expectations for the 2023 readouts," but Jallah believes that macro events affecting the market and a "flight of investors out of the biotech sector" led to a muted reaction to the data, the analyst added.
KOD
$7.25-0.31(-4.10%)11:00 AM 11/14/22
NASDAQ |$USD |Pre-Market:$7.51+0.26(+3.59%)3:48 AM
Small reaction-
/////////////////////
NeuroSense rises 16% on U.S. FDA clearance to begin trial of ALS treatment
Watch For Gummy!// wait for GO TIME<---------
NRSN
$1.580.06(+4.30%)10:59 AM 11/14/22
NASDAQ |$USD |Pre-Market:$1.74+0.17(+10.48%)<----------
BUY VAN!!!!!
& Sell! Just made you 5%
NRSN NeuroSense Therapeutics Ltd.
$1.580.06(+4.30%)10:59 AM 11/14/22
NASDAQ |$USD |Pre-Market:$1.81+0.24(+14.92%)4:15 AM
<<2 Possible Gummies>>
Kodiak Sciences initiated with an Overweight at Capital One 08:27 KOD Capital One analyst Zegbeh Jallah initiated coverage of Kodiak Sciences with an Overweight rating and $24 price target. Kodiak's long-acting anti-VEGF drug Tarcocimab, or KSI-301, is currently in Phase 3 studies for DME, wAMD and NPDR with data expected in 2023, Jallah tells investors. Data from the Phase 3 BEACON study presented in September reaffirmed KSI-301's longer-acting potential and clean safety profile and "sets positive expectations for the 2023 readouts," but Jallah believes that macro events affecting the market and a "flight of investors out of the biotech sector" led to a muted reaction to the data, the analyst added.
KOD
$7.25-0.31(-4.10%)11:00 AM 11/14/22
NASDAQ |$USD |Pre-Market:$7.51+0.26(+3.59%)3:48 AM
Small reaction-
/////////////////////
NeuroSense rises 16% on U.S. FDA clearance to begin trial of ALS treatment
Watch For Gummy!// wait for GO TIME<---------
NRSN
$1.580.06(+4.30%)10:59 AM 11/14/22
NASDAQ |$USD |Pre-Market:$1.74+0.17(+10.48%)<----------
BUY VAN!!!!!
& Sell! Just made you 5%
NRSN NeuroSense Therapeutics Ltd.
$1.580.06(+4.30%)10:59 AM 11/14/22
NASDAQ |$USD |Pre-Market:$1.81+0.24(+14.92%)4:15 AM
You really like to mindfuck me Why? Last huge gummy we had was for 60% in 1 day and you found some problem with that -wasn't sure when to buy... I'm not buying your naivete
or or pretend lack of knowledge.. so I go out of my way to scream the obvious I always do wait for my signal on the retrace...
and you pretend you read the opposite -- that your a dummy again...
just not buying it....
or or pretend lack of knowledge.. so I go out of my way to scream the obvious I always do wait for my signal on the retrace...
and you pretend you read the opposite -- that your a dummy again...
just not buying it....